CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
(via SciShow) CRISPR-based gene therapies are already changing healthcare for things like sickle cell disease. But CRISPR is bigger than just medicine, and it could revolutionize everything from food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results